BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- Bruno Bockorny
- , Valerya Semenisty
- , Teresa Macarulla
- , Erkut Borazanci
- , Brian M. Wolpin
- , Salomon M. Stemmer
- , Talia Golan
- , Ravit Geva
- , Mitesh J. Borad
- , Katrina S. Pedersen
- , Joon Oh Park
- , Robert A. Ramirez
- , David G. Abad
- , Jaime Feliu
- , Andres Muñoz
- , Mariano Ponz-Sarvise
- , Amnon Peled
- , Tzipora M. Lustig
- , Osnat Bohana-Kashtan
- , Stephen M. Shaw
- Beth Israel Deaconess Medical Center
- Harvard University
- Oncology Institute
- Vall d’Hebron University Hospital
- HonorHealth, Arizona
- Translational Genomics Research Institute
- Dana-Farber Cancer Institute
- Rabin Medical Center Israel
- Tel Aviv University
- Sheba Medical Center at Tel Hashomer
- Tel Aviv Sourasky Medical Center
- Mayo Clinic Scottsdale-Phoenix, Arizona
- Washington University St. Louis
- Ochsner Health System
- Grupo Oncologia Fuenlabrada
- Hospital Universitario La Paz
- Complutense University
- University of Navarra
- Hebrew University of Jerusalem
- BioLineRx, Ltd.
- Merck
- StatExcellence Ltd
- Cornell University
- New York Presbyterian Hospital
Research output: Contribution to journal › Article › peer-review
485
Link opens in a new tab
Scopus
citations